Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 4, 2009

Private Equity Firm to Take Over PharmaNet for $100M

  • JLL Partners has agreed to acquire PharmaNet Development Group for about $100 million. JLL will pay $5.00 per share, more than three times PharmaNet’s closing price on February 2, the day before the transaction was made public. PharmaNet’s stock jumped to over $4 during trading yesterday.

    The transaction will be financed by a $250 million equity commitment from JLL, which includes the necessary funds to retire the $144 million principal amount of the company's outstanding convertible notes. The parties expect the tender offer to close by the end of this quarter.

    PharmaNet provides a range of services to the pharmaceutical, biotechnology, generic drug, and medical device industries. The company offers early- and late-stage consulting, Phase I studies and bioanalytical analyses, as well as Phase II, III, and IV clinical development programs. It has approximately 2,500 employees and 41 facilities throughout the world.

    ---

     



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »